RSV Prefusion F3 Vaccine in Lung Transplant Recipients elicits CD4+ T-cell response in all Vaccinees
American Journal of Transplantation,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 1, 2025
Language: Английский
Vaccination strategies for solid organ transplant candidates and recipients: insights and recommendations
Expert Review of Vaccines,
Journal Year:
2025,
Volume and Issue:
unknown
Published: April 4, 2025
Vaccines
save
lives.
They
are
integral
to
reducing
the
morbidity
and
mortality
of
vaccine
preventable
infections
in
solid
organ
transplant
recipients.
Pre-transplant
vaccination
provides
a
unique
opportunity
for
administration
live,
viral
vaccines
enhanced
efficacy,
compared
post-transplant
period
with
decreased
response
due
immunosuppression.
We
discuss
general
approach
pre-
candidates
then
review
guideline
statements
recent
literature
related
individual
vaccines,
including
recently
developed
respiratory
syncytial
virus
vaccine.
Travel
occupation-related
also
discussed.
The
challenge
immunocompromised
patients
expands
as
prevalence
adults
rises,
frequently
excluded
from
trials.
In
an
age
hesitancy
reemerging
infections,
well-powered,
prospective
studies
needed
evaluate
clinical
effectiveness
Language: Английский
Neutralizing Antibody Response to the AreXvy Respiratory Syncytial Virus Vaccine in Lung Transplant Recipients: Assessment Against Reference and Seasonal Strains
Liran Levy,
No information about this author
Dafna Yahav,
No information about this author
M. Benzimra
No information about this author
et al.
Vaccines,
Journal Year:
2025,
Volume and Issue:
13(4), P. 398 - 398
Published: April 11, 2025
Respiratory
Syncytial
Virus
(RSV)
is
a
significant
cause
of
morbidity
and
mortality
among
lung
transplant
(LTx)
recipients.
Therapeutic
options
are
limited,
emphasizing
the
importance
prevention.
The
Arexvy®
vaccine
(RSVPreF3)
showed
promising
efficacy
immunocompetent
adults;
however,
data
on
its
immunogenicity
in
solid
organ
recipients
remain
unclear.
A
single-center
retrospective
cohort
study,
including
all
LTx
who
were
vaccinated
with
Arexvy
February
2024.
Baseline
follow-up
serum
samples
(1,
3,
6
months
post-vaccination)
analyzed
for
antibody
responses
using
commercial
RSV
ELISA
kit
micro-neutralization
assays
against
historical
reference
A/B
ATCC
strains
seasonal
strains.
Adverse
events
documented.
total
28
received
vaccine.
Twenty-one
(75%)
male,
median
age
was
62
years
(interquartile
range
[IQR],
53-67).
time
from
486
days
(IQR,
243-966).
Vaccination
elicited
strong
immunogenic
responses,
demonstrating
twofold
increase
ELISA-determined
levels
at
one
month
post-vaccination,
which
sustained
six
months.
At
month,
67%
had
exceeding
cutoff
threshold.
Micro-neutralization
neutralizing
antibodies
tested
variants
(RSV
A/B),
titers
remaining
least
higher
than
pre-vaccination
levels.
No
serious
adverse
observed.
Our
findings
demonstrate
response
to
recipients,
over
Further
research
needed
assess
long-term
durability
immune
potential
this
populations.
Language: Английский
Minding the gap: How transplant infectious disease can help close the organ donation gap
Rachel Sigler,
No information about this author
Nancy Law
No information about this author
Transplant Infectious Disease,
Journal Year:
2024,
Volume and Issue:
26(S1)
Published: Sept. 28, 2024
Abstract
This
paper
is
an
educationally
focused
article
discussing
how
transplant
infectious
diseases
(TID)
providers
balance
the
risks
of
accepting
or
rejecting
organ
and
have
pushed
barriers
in
transplantation.
We
emphasize
role
TID
play
transplantation
process
as
critical
players
on
team.
discuss
various
donor‐derived
infections
that
were
previously
deemed
unacceptable
for
donation
due
to
concerns
transmission.
Advances
medical
knowledge
changed
some
these
situations.
closing
gap
between
thousands
patients
waitlists
deficit
faced
each
day.
believe
a
unique
opportunity
expand
donor
pool
by
increasing
education,
expanding
acceptable
definitions,
boundaries
what
we
can
do
with
potentially
transmissible
Language: Английский